On June 30, RemeGen (09995.HK) fell 5.27% in regular trading, trading at HKD 75.5 per share, with turnover of HKD 292 million.

On the news front, 192.8 million IPO restricted shares — representing 34.16% of total share capital and corresponding to an unlock value of approximately RMB 21.79 billion — are scheduled to begin trading on July 1, making it the second-largest single-stock unlock on A-shares for the week. The massive unlock comes one day after the stock surged over 16% on June 29, driven by positive clinical data for its ADC drug Disitamab Vedotin and broader sector tailwinds from innovative drug commercialization momentum. The combination of impending supply overhang and profit-taking from the prior session rally pressured shares.

Notably, the company disclosed that because cash dividends have not met regulatory thresholds under Shanghai Stock Exchange self-regulatory guidelines, the unlocking shareholders are prohibited from reducing holdings via centralized bidding or block trades, meaning actual selling pressure remains substantially lower than headline figures suggest.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)